H. Lundbeck A/S Overview
Pro stress-test →Lundbeck engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company is a specialized CNS (central nervous system) pharmaceutical leader with a portfolio spanning depression, schizophrenia, epilepsy, Parkinson's disease, and migraine prevention.
Strategic Profile
Pro stress-test →Strong growth in strategic brands and expansion into international markets positions Lundbeck to benefit from rising diagnosis and treatment rates in brain health. A maturing pipeline and capital redeployment into innovative assets underpin long-term portfolio diversification and support future revenue and margin improvement.
Competitive Landscape
Pro stress-test →Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company competes with larger pharma players in CNS therapeutics, differentiating through specialized portfolio focus and emerging market expansion. Major competitors include Eli Lilly (Cymbalta, Prozac), Pfizer (Lyrica), Allergan (Botox for migraine), and smaller specialized CNS firms.
Industry Context
H. Lundbeck A/S operates in Pharmaceuticals - Specialty (CNS/Neurological Focus).
Key facts
Founded: 1915 · Headquarters: Copenhagen, Denmark · Employees: 5,039 · Revenue: $3.72B · Market cap: $5.95B